This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Zanubrutinib for treating Waldenstrom's macroglobulinaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Zanubrutinib for treating Waldenstrom's macroglobulinaemia (WM)

Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitors that was developed to achieve BTK inhibiting efficacy while reducing the off-target adverse events documented with ibrutinib therapy

  • has high specificity for the BTK adenosine triphosphate binding site for cysteine 481, zanubrutinib covalently binds to this site, resulting in irreversible, sustainable kinase inhibition
  • ibrutinib, showed great efficacy in treating WM
    • however, response rates were dependent on whether patients had the CXCR4 mutation, a molecular aberration that may confer resistance to BTK inhibitors
    • ibrutinib's toxicities, most notably hypertension and atrial arrhythmia, led to dose reductions or discontinuation
    • toxicity profile of ibrutinib can be attributed to the inhibition of additional kinases that are structurally related to BTK

NICE state:

  • Zanubrutinib is recommended as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if:
    • bendamustine plus rituximab is also suitable and
    • the company provides it according to the commercial arrangement

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.